Evonik, JeNaCell strengthen ties.
* GERMANY: Innovation and business opportunities were the focus of a recent visit by Evonik chairman Klaus Engel at JeNaCell, the spinoff venture of Friedrich Schiller University. Evonik acquired a minority share in the company, which was founded in 2012 by two chemists, Nadine Hefiler and Dana Kralisch.
"The company is an outstanding example of industrial biotechnology's potential. It is impressive to witness how scientific research is turned into market-ready products here. This is true entrepreneurial spirit," said Engel during a tour of the production facilities.
For Evonik, the collaboration with JeNaCell offers access to nanocellulose, which can serve as a carrier system for cosmetic and medical active ingredients. The companies have already initiated the first joint projects in this area. In addition, JeNaCell is working with process technology engineers from Evonik to look into ways of further expanding the scale of its nanocellulose production process.
At the Bioinstrumentation Center in Jena, Engel was briefed on the company's expanding production and the market launch of new products.
JeNaCell is currently preparing the market launch of a new product line in the area of dermatology. The products are used to aid therapeutic measures in medical cosmetology, laser treatments and skin sensitivities or to supplement aesthetic procedures such as exfoliation. As documented by current studies, they have a long-lasting moisturizing, cooling and soothing effect on the skin and support the natural regeneration of sensitive skin.
Evonik intends to invest some 100 million [euro] in promising start-ups with innovative technologies and in leading specialized venture capital funds as part of its venture capital activities. Regional focus areas include Europe, the US and Asia. Evonik currently holds shares in eight start-ups and four funds.
More info: http://venturing.evonik.com